Pasar al contenido principal

DISEÑO Y EVALUACION DE SISTEMAS MICROPARTICULARES BIODEGRADABLES DE AGENTES NEUROPROTECTORES PARA EL TRATAMIENTO DE PATOLOGIAS NEURODEGENERATIVAS OCULARES

MAT2010-18242

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2010
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Proyectos de Investigación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Six month delivery of GDNF from PLGA/vitamin E biodegradable microspheres after intravitreal injection in rabbits

  • García-Caballero, C.
  • Prieto-Calvo, E.
  • Checa-Casalengua, P.
  • García-Martín, E.
  • Polo-Llorens, V.
  • García-Feijoo, J.
  • Molina-Martínez, I.T.
  • Bravo-Osuna, I.
  • Herrero-Vanrell, R.
Local long-term delivery of glial cell line derived neurotrophic factor (GDNF) from vitamin E/poly-lactic-co-glycolic acid microspheres (MSs) protects retinal ganglion cells in an animal model of glaucoma for up to 11 weeks. However, the pharmacokinetics of GDNF after intravitreal injection of MSs is not known. We evaluated the GDNF levels after a single intravitreal injection of GDNF/VitE MSs. Biodegradable MSs were prepared by the solid-oil-in-water emulsion-solvent evaporation technique and characterized. Rabbits received a single intravitreal injection (50 µL) of GDNF/VitE MSs (4%w/v; 24 right eyes; 74.85 ng GDNF), blank MSs (4%w/v; 24 left eyes), and balanced salt solution (4 eyes). Two controls eyes received no injections. At 24 h, 1, 4, 6, 8, 12, 18, and 24 weeks after injection, the eyes were enucleated, and the intravitreal GDNF levels were quantified. Pharmacokinetic data were analysed according to non-compartmental model. Intraocular GDNF levels of 717.1 ± 145.1 pg/mL were observed at 24 h for GDNF-loaded MSs, followed by a plateau (745.3 ± 25.5 pg/mL) until day 28. After that, a second plateau (17.4 ± 3.7 pg/mL) occurred from 8 to 24 weeks post-injection, significantly higher than the basal levels. Eyes injected with GDNF/vitE and Blank-MSs did not show any abnormalities during the six-months follow up after administration. The single injection of GDNF/VitE MSs provided a sustained controlled release of the neurotrophic factor in a controlled fashion for up to six months.